Sermorelin
Sermorelin is a synthetic GHRH fragment studied for pulsatile growth hormone release and somatotropic-axis signaling.
What Sermorelin is
Sermorelin is the 1-29 amino acid fragment of growth hormone-releasing hormone and retains the core biological activity needed to stimulate pituitary GH release in research settings. It has been studied as a diagnostic and investigational endocrine tool, especially where researchers want to evaluate somatotropic-axis responsiveness rather than administer growth hormone directly.
The literature includes intravenous, intranasal, and subcutaneous contexts, with strong attention to GH pulses, IGF-1 changes, pharmacokinetics, and route-dependent bioavailability. Research-grade sermorelin is not an approved drug product for casual use and is commonly labeled Research Use Only. Reported ranges below summarize published study exposure ranges, not recommendations.
How it works
Sermorelin binds the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs. Receptor activation increases cAMP signaling and promotes pulsatile growth hormone secretion when pituitary reserve is present. Because the molecule acts upstream of GH release, research readouts often include GH peak, GH area under the curve, IGF-1 changes, and route-dependent absorption. Intranasal bioavailability has been reported as low relative to intravenous administration.
Who studies it, and why
Sermorelin is studied by endocrinologists, pediatric growth researchers, pharmacokinetic teams, and anti-doping laboratories. It is also examined by analytical chemists because GHRH analogs require careful detection and identity testing.
What the research examines
Research areas, not results. A topic on this list is being studied, not settled.
How it appears in the literature
Amounts reported in published research, shown for reference. Not a protocol.
| Research context | Reported amount | Frequency | Route |
|---|---|---|---|
| Normal-volunteer GHRH(1-29)-NH2 bolus study, expressed as approximate 70 kg equivalent | 1.05 mcg – 35 mcg | single bolus in study protocol | intravenous |
| Healthy-men pharmacokinetic study, approximate 70 kg equivalent | 17.5 mcg – 140 mcg | single administration in study protocol | intravenous |
| Intranasal research exposure in healthy men, approximate 70 kg equivalent | 350 mcg – 3.5 mg | single or repeated study administrations | intranasal |
Handling & storage
Lyophilized sermorelin is commonly kept frozen or refrigerated per supplier specifications, protected from moisture; reconstituted research solutions are generally refrigerated and handled aseptically.
Notes on combined research
Sermorelin is often discussed with other GH secretagogues, but combined protocols can make GH, IGF-1, glucose, and sleep-related endpoints hard to attribute. Research designs usually control timing, fasting state, and co-administered secretagogues carefully because pituitary response is pulsatile and context-sensitive.
Sermorelin questions
Published studies report route-specific research exposures, including mcg/kg intravenous and intranasal protocols. These are literature references, not dosing instructions.
Common research reconstitution examples use 1-3 mL for small vials. The volume only changes concentration math; it does not define a recommended amount.
Daily sermorelin discussions usually come from clinical or research protocols with defined endpoints. For education pages, the route, frequency, and population should be kept separate.
A chart should show vial strength, reconstitution volume, concentration, and cited study context. It should not turn literature values into personal-use instructions.
GH response in challenge studies can occur within minutes to hours, while IGF-1 or downstream endocrine readouts require longer study windows.
Sermorelin has a short plasma half-life. Researchers often care more about the GH pulse it triggers than about prolonged peptide exposure.
It can be studied with other secretagogues, but stacking complicates interpretation. Research-only materials are not for human consumption.
Read the research yourself
These references were validated against the NCBI database. No citation appears here unless it resolves to a real paper.
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.PubMed
- Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men.PubMed
- Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration.PubMed